已收盤 11-20 16:00:00 美东时间
-0.250
-17.86%
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
11-21 21:28
Acrivon Therapeutics, Inc. ( ($ACRV) ) has issued an update. On November 20, 20...
11-21 05:37
今日重点评级关注:Ascendiant Capital:维持Allarity Therapeutics"买入"评级,目标价从11美元升至11.25美元;康托·菲茨杰拉德:维持Cypherpunk Technologies"超配"评级,目标价从4.9美元升至5美元
11-18 15:28
11月18日,Acrivon Therapeutics(ACRV)收跌2.05%,报1.43美元,成交额62.87万美元,市值6128.04万美元。 行情数据...
11-18 08:15
Citizens analyst Silvan Turkcan reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Market Outperform and maintains $13 price target.
11-17 22:17
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.46) by 8.7 percent. This is a 10.64 percent increase over losses of $(0.47) per share from the same period last year.
11-17 05:21
Acrivon Therapeutics reported third-quarter 2026 financial results and highlighted progress in its oncology and immunology pipelines. The company expanded its focus into immunology and inflammation, leveraging its AI-driven AP3 platform to identify novel therapies. Key developments include ACR-525, a JAK1 inhibitor targeting eosinophilic esophagitis, and ACR-2316, a WEE1/PKMYT1 inhibitor showing promising safety and efficacy in lung cancers. ACR-...
11-16 21:05
11月11日,Acrivon Therapeutics(ACRV)收跌0.63%,报1.57美元,成交额12.81万美元,市值6727.95万美元。 行情数据...
11-11 08:11
Acrivon Therapeutics, Inc. ( ($ACRV) ) has shared an update. On November 6, 202...
11-06 21:33
Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative AI-driven Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for ...
11-06 21:02